Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Measured Wealth Private Client Group LLC

Measured Wealth Private Client Group LLC lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 5.0% during the third quarter, HoldingsChannel reports. The firm owned 8,110 shares of the company’s stock after purchasing an additional 384 shares during the quarter. Measured Wealth Private Client Group LLC’s holdings in Merck & Co., Inc. were worth $673,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Papp L Roy & Associates lifted its position in shares of Merck & Co., Inc. by 1.2% during the second quarter. Papp L Roy & Associates now owns 10,351 shares of the company’s stock worth $800,000 after purchasing an additional 126 shares in the last quarter. Ferris Capital LLC lifted its position in shares of Merck & Co., Inc. by 2.9% during the second quarter. Ferris Capital LLC now owns 4,539 shares of the company’s stock worth $351,000 after purchasing an additional 129 shares in the last quarter. Pure Financial Advisors Inc. lifted its position in shares of Merck & Co., Inc. by 0.7% during the second quarter. Pure Financial Advisors Inc. now owns 19,480 shares of the company’s stock worth $1,506,000 after purchasing an additional 136 shares in the last quarter. GYL Financial Synergies LLC lifted its position in shares of Merck & Co., Inc. by 3.4% during the second quarter. GYL Financial Synergies LLC now owns 4,091 shares of the company’s stock worth $316,000 after purchasing an additional 136 shares in the last quarter. Finally, Shorepoint Capital Partners LLC lifted its position in shares of Merck & Co., Inc. by 0.4% during the second quarter. Shorepoint Capital Partners LLC now owns 32,586 shares of the company’s stock worth $2,520,000 after purchasing an additional 137 shares in the last quarter. 73.18% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently issued reports on the stock. Goldman Sachs Group raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and upped their price target for the company from $91.00 to $105.00 in a report on Monday, August 3rd. Mizuho reaffirmed a “buy” rating on shares of Merck & Co., Inc. in a report on Tuesday, September 22nd. Berenberg Bank assumed coverage on shares of Merck & Co., Inc. in a report on Tuesday, September 29th. They issued a “hold” rating and a $88.00 price target on the stock. Royal Bank of Canada reaffirmed a “hold” rating on shares of Merck & Co., Inc. in a report on Tuesday, August 4th. Finally, SVB Leerink upped their price target on shares of Merck & Co., Inc. from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $95.08.

MRK stock opened at $79.83 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.32 and a quick ratio of 1.05. Merck & Co., Inc. has a 1-year low of $65.25 and a 1-year high of $92.64. The firm has a fifty day moving average price of $83.27 and a two-hundred day moving average price of $80.42. The firm has a market cap of $201.91 billion, a price-to-earnings ratio of 19.47, a PEG ratio of 2.10 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Friday, July 31st. The company reported $1.37 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.23. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The firm had revenue of $10.87 billion during the quarter, compared to analyst estimates of $10.52 billion. During the same quarter in the previous year, the firm earned $1.30 earnings per share. The firm’s revenue for the quarter was down 7.6% compared to the same quarter last year. As a group, analysts expect that Merck & Co., Inc. will post 5.68 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were paid a dividend of $0.61 per share. The ex-dividend date was Monday, September 14th. This represents a $2.44 annualized dividend and a yield of 3.06%. Merck & Co., Inc.’s payout ratio is 47.01%.

In other news, CFO Robert M. Davis sold 251,273 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $81.03, for a total transaction of $20,360,651.19. Following the completion of the transaction, the chief financial officer now owns 422,329 shares in the company, valued at $34,221,318.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Frank Clyburn sold 18,876 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $81.55, for a total transaction of $1,539,337.80. Following the transaction, the executive vice president now owns 99,639 shares of the company’s stock, valued at approximately $8,125,560.45. The disclosure for this sale can be found here. In the last quarter, insiders have sold 280,529 shares of company stock valued at $22,761,633. 0.28% of the stock is owned by insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: Can systematic risk be avoided?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.